Outcomes of the First Pregnancy After Fertility-Sparing Surgery for Early-Stage Cervical Cancer.


Journal

Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101

Informations de publication

Date de publication:
01 10 2021
Historique:
received: 30 04 2021
accepted: 24 06 2021
entrez: 8 10 2021
pubmed: 9 10 2021
medline: 18 12 2021
Statut: ppublish

Résumé

To evaluate outcomes of the first pregnancy after fertility-sparing surgery in patients with early-stage cervical cancer. We performed a population-based study of women aged 18-45 years with a history of stage I cervical cancer reported to the 2000-2012 California Cancer Registry. Data were linked to the OSHPD (California Office of Statewide Health Planning and Development) birth and discharge data sets. We included patients with cervical cancer who conceived at least 3 months after a fertility-sparing surgery, which included cervical conization or loop electrosurgical excision procedure. Those undergoing trachelectomy were excluded. The primary outcome was preterm birth. Secondary outcomes included growth restriction, neonatal morbidity, stillbirth, cesarean delivery, and severe maternal morbidity. We used propensity scores to match similar women from two groups in a 1:2 ratio of case group participants to control group participants: population individuals without cancer and individuals with cervical cancer (women who delivered before their cervical cancer diagnosis). Wald statistics and logistic regressions were used to evaluate outcomes. Of 4,087 patients with cervical cancer, 118 (2.9%) conceived after fertility-sparing surgery, and 107 met inclusion criteria and were matched to control group participants. Squamous cell carcinoma was the most common histology (63.2%), followed by adenocarcinoma (30.8%). Patients in the case group had higher odds of preterm birth before 37 weeks of gestation compared with both control groups (21.5% vs 9.3%, odds ratio [OR] 2.7, 95% CI 1.4-5.1; 21.5% vs 12.7%, OR 1.9, 95% CI 1.0-3.6), but not preterm birth before 32 weeks. Neonatal morbidity was more common among the patients in the case group relative to those in the cervical cancer control group (15.9% vs 6.9%, OR 2.5, 95% CI 1.2-5.5). There were no differences in rates of growth restriction, stillbirth, cesarean delivery, and maternal morbidity. In a population-based cohort, patients who conceived after surgery for cervical cancer had higher odds of preterm delivery compared with control groups.

Identifiants

pubmed: 34623068
doi: 10.1097/AOG.0000000000004532
pii: 00006250-202110000-00007
pmc: PMC8693797
mid: NIHMS1754926
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

565-573

Subventions

Organisme : NCI NIH HHS
ID : K08 CA234333
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001874
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA101642
Pays : United States

Informations de copyright

Copyright © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

Financial Disclosure Mark A. Clapp reports that money was paid to him from the American Association of Obstetricians and Gynecologists Foundation. Larissa A. Meyer reports that money was paid to her institution from AstraZeneca, and money was paid to her from GlaxoSmithKline. The other authors did not report any potential conflicts of interest.

Références

Int J Gynecol Cancer. 2013 Sep;23(7):1171-7
pubmed: 23970154
Fertil Steril. 2021 May;115(5):1250-1258
pubmed: 33589139
Am J Obstet Gynecol. 2006 Apr;194(4):992-1001
pubmed: 16580288
BJOG. 2018 Dec;125(13):1726-1733
pubmed: 30099822
Gynecol Oncol. 2020 May;157(2):418-422
pubmed: 32122687
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Oncotarget. 2017 Jul 11;8(28):46580-46592
pubmed: 28418849
Acta Obstet Gynecol Scand. 2019 Jun;98(6):777-786
pubmed: 30667051
Obstet Gynecol. 2018 Jun;131(6):1085-1094
pubmed: 29742670
Pediatrics. 2019 Jul;144(1):
pubmed: 31201230
Int J Cancer. 2017 Dec 1;141(11):2187-2196
pubmed: 28836277
Obstet Gynecol. 2018 May;131(5):899-908
pubmed: 29630020
Health Serv Res. 2000 Oct;35(4):869-83
pubmed: 11055453
J Obstet Gynaecol Res. 2016 Dec;42(12):1796-1801
pubmed: 27528387
Am J Obstet Gynecol MFM. 2020 Aug;2(3):100168
pubmed: 33345887
Cancers (Basel). 2021 Feb 28;13(5):
pubmed: 33670929
N Engl J Med. 2018 Aug 09;379(6):513-523
pubmed: 30089070
Am J Obstet Gynecol. 2018 Nov;219(5):461.e1-461.e18
pubmed: 30138618
Int J Environ Res Public Health. 2020 Sep 28;17(19):
pubmed: 32998288
Gynecol Oncol. 2011 May 1;121(2):290-7
pubmed: 21255824
Obstet Gynecol. 2020 Dec;136(6):1157-1169
pubmed: 33156194
Fertil Steril. 2016 Oct;106(5):1195-1211.e5
pubmed: 27430207
Int J Gynecol Cancer. 2015 Mar;25(3):493-7
pubmed: 25628110
Am J Perinatol. 2007 Oct;24(9):531-9
pubmed: 17899494
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Natl Vital Stat Rep. 2019 Nov;68(13):1-47
pubmed: 32501202
JAMA Oncol. 2017 Aug 1;3(8):1078-1084
pubmed: 28334337
Fertil Steril. 2020 Apr;113(4):685-703
pubmed: 32228873
PLoS One. 2018 Aug 23;13(8):e0202805
pubmed: 30138451
Int J Clin Oncol. 2017 Apr;22(2):340-346
pubmed: 27804040
Cochrane Database Syst Rev. 2017 Nov 02;11:CD012847
pubmed: 29095502
Int J Gynecol Cancer. 2013 Feb;23(2):218-26
pubmed: 23314281
Int J Gynecol Cancer. 2021 Mar;31(3):457-461
pubmed: 33649014
Am J Public Health. 1998 May;88(5):813-6
pubmed: 9585754
Int J Gynecol Cancer. 2021 Mar;31(3):452-456
pubmed: 33649013

Auteurs

Roni Nitecki (R)

Department of Gynecologic Oncology and Reproductive Medicine, the Department of Health Services Research, Division of Cancer Prevention and Population Sciences, and the Department of Breast Medical Oncology, the University of Texas MD Anderson Cancer Center, and the Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas; the Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas; the Department of Obstetrics and Gynecology, Massachusetts General Hospital, the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, and the Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, Massachusetts; and the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University Vagelos College of Physicians and Surgeons, and the Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH